ClinicalTrials.govpublic full text
Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib
non-small cell lung cancer, egfr gene mutation, gefitinib, anlotinib, tkis, antivascular therapy, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 1046333
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.